Clinical trials: Recurrent GBM
Malignant Glioma of Brain
Study of Acetazolamide With Temozolomide in Adults With Newly Diagnosed or Recurrent Malignant Glioma
This is a Phase I study that examines the rate of dose limiting side effects in patients with malignant astrocytoma treated with combination acetazolamide (ACZ) and temozolomide (TMZ).
- Trial name
- NCT03011671
- Testing
- Acetazolamide, Temozolomide
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Chicago
Glioblastoma
Study on Low Dose Temozolomide Plus Metformin or Placebo in Patient With Recurrent or Refractory Glioblastoma
A phase 2 clinical trial for the efficacy and safety of low dose Temozolomide plus metformin as combination chemotherapy compared with low dose Temozolomide plus placebo in patient with recurrent or refractory Glioblastoma
- Trial name
- METT (NCT03243851)
- Testing
- Temozolomide+Metformin
- Where
- 12 sites in South Korea
- Volunteers
- 81 people
- Sponsor
- Yong-Kil Hong
Glioblastoma Multiforme
A Study of MEDI-575 in Subjects With Recurrent Glioblastoma Multiforme
The primary objective of this Phase II study is to evaluate the progression-free survival at 6 months in adult subjects with a first recurrence of Glioblastoma Multiforme who are treated with MEDI-575.
- Trial name
- NCT01268566
- Testing
- MEDI-575
- Where
- 12 sites in United States
- Volunteers
- 62 people
- Sponsor
- MedImmune LLC
Glioblastoma, Astrocytoma
Efficacy and Safety of Temodal vs Semustine in Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma (Study P03644)
The primary purpose of the study is to evaluate the efficacy and safety of temozolomide compared to semustine in the treatment of patients with glioblastoma multiforme or anaplastic astrocytoma.
- Trial name
- NCT00335075
- Testing
- Temozolomide, Semustine
- Volunteers
- 151 people
- Sponsor
- Merck Sharp & Dohme LLC
Recurrent High-grade Glioma, Grade III Astrocytoma
Peds CHAMP1ON - Hematopoietic Stem Cell And Monoclonal Antibody PD-1 Blockade for RecurreNt Pediatric High-Grade Glioma
This is a Phase I study of ex vivo expanded CD34+ hematopoietic stem cells (exHSCs) plus nivolumab in pediatric patients with histologically confirmed diagnosis of a non-brainstem high-grade glioma (NB-HGG, WHO Grade III or IV…
- Conditions
- Recurrent High-grade Glioma, Grade III Astrocytoma, Oligodendroglioma, Oligoastrocytoma
- Trial name
- Peds CHAMP1ON (NCT07031765)
- Testing
- exHSC, Nivolumab, Resection or biopsy
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Florida
Glioblastoma Multiforme, Brain Tumor, Adult: Glioblastoma
Multimodality MRI and Liquid Biopsy in GBM
Patients with a new diagnosis of high-grade glioma based on MRI, who are considered surgical candidates determined by neurosurgeons or patients with recurrent glioblastoma with the initial diagnosis of glioblastoma (histologic or…
- Conditions
- Glioblastoma Multiforme, Brain Tumor, Adult: Glioblastoma, Brain Tumor, Recurrent, Brain Tumor, Primary
- Trial name
- NCT04776980
- Testing
- Post Feraheme Infusion MRI
- Where
- United States
- Sponsor
- Abramson Cancer Center at Penn Medicine
Brain Tumor, Anaplastic Astrocytoma
Ritonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade Glioma
RATIONALE: Ritonavir and lopinavir may stop the growth of gliomas by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Brain Tumor, Anaplastic Astrocytoma, Anaplastic Ependymoma, Anaplastic Oligodendroglioma
- Trial name
- NCT01095094
- Testing
- ritonavir, lopinavir
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Case Comprehensive Cancer Center
Brain and Central Nervous System Tumors
EMD 121974 in Treating Patients With Progressive or Recurrent Glioma
RATIONALE: EMD 121974 may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: Phase I/II trial to study the effectiveness of EMD 121974 in treating patients who have progressive or recurrent malignant glioma.
- Trial name
- NCT00006093
- Testing
- cilengitide
- Where
- 10 sites in United States
- Sponsor
- New Approaches to Brain Tumor Therapy Consortium
Glioblastoma Multiforme
Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy
The purpose of this study is to evaluate the safety, maximum tolerated dose (MTD), and efficacy of TPI 287 in combination with Avastin (bevacizumab) in subjects who have glioblastoma multiforme (GBM) that has progressed following…
- Trial name
- NCT02047214
- Testing
- TPI 287, Bevacizumab
- Where
- 11 sites in United States
- Volunteers
- 17 people
- Sponsor
- Cortice Biosciences, Inc.
Glioblastoma Multiforme, Glioblastoma
Efficacy and Safety of NaviFUS System add-on Bevacizumab (BEV) in Recurrent GBM Patients
This is a prospective, single-arm, two stages, open-label, pilot study to investigate the efficacy and safety of FUS add-on bevacizumab (BEV) in rGBM patients.
- Conditions
- Glioblastoma Multiforme, Glioblastoma, Glioma, Brain Tumor
- Trial name
- NCT04446416
- Testing
- NaviFUS System, Bevacizumab
- Where
- Taiwan
- Volunteers
- 6 people
- Sponsor
- NaviFUS Corporation
Glioblastoma, Recurrent Glioblastoma
ASP8374 + Cemiplimab in Recurrent Glioma
This study is looking at the safety and efficacy of the drug combination of ASP8374 with cemiplimab in people with recurrent malignant glioma.
- Trial name
- NCT04826393
- Testing
- ASP8374, cemiplimab
- Where
- 4 sites in United States
- Volunteers
- 14 people
- Sponsor
- Dana-Farber Cancer Institute
Recurrent Glioblastoma
BIBF 1120 in Recurrent Glioblastoma Multiforme
VEGF inhibition by BEV may induce a change in tumor invasiveness and treatment failure is often associated with remote metastases. BEV may stop the growth of tumor cells by blocking blood flow to the tumor.
- Trial name
- NCT01251484
- Testing
- BIBF1120
- Where
- Denmark
- Volunteers
- 25 people
- Sponsor
- Ulrik Lassen
Brain and Central Nervous System Tumors
Study of Blood and Cheek Cell Samples From Patients With Glioma
RATIONALE: Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT01009307
- Testing
- polymorphism analysis, laboratory biomarker analysis, medical chart review
- Where
- United States
- Volunteers
- 1,709 people
- Sponsor
- University of California, San Francisco
Recurrent Glioblastoma Multiforme
A Prospective, Open-label, Single-arm Clinical Study
the study is a prospective, single-arm, open-label trial, designed to explore the efficacy and safety of Tumor-Treating Fields (TTFields) combined with second-line chemotherapy treatment in recurrent glioblastoma multiforme (GBM)…
- Trial name
- NCT04689087
- Testing
- TTFields
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sun Yat-sen University
Glioblastoma Multiforme (GBM), Pancreatic Ductal Adenocarcinoma (PDAC)
Study of 203Pb-RMX-VH-PIB Dosimetry and Biodistribution in Patients With Glioblastoma Multiform (GBM) and Pancreatic Ductal Adenocarcinoma (PDAC)
The goal of this Phase I clinical trial is to evaluate how the imaging drug 203Pb- RMX-VH-PIB distributes in the body and how much radiation different organs receive in patients with glioblastoma multiforme (GBM) or pancreatic…
- Trial name
- RMX-VH (NCT07733674)
- Testing
- 203Pb-RMX-VHPIB injection, SPECT/CT Imaging
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Radiomedix, Inc.
Glioblastoma (GBM), Diffuse Midline Glioma (DMG)
Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade Glioma
This is a single-arm open-label phase 1 dose escalation/expansion trial assessing the safety and efficacy of concurrent intrathecal azacitidine and intrathecal nivolumab in recurrent high-grade glioma.
- Conditions
- Glioblastoma (GBM), Diffuse Midline Glioma (DMG), Astrocytoma, IDH-Mutant, Grade 4, Diffuse Hemispheric Glioma, H3 G34-Mutant
- Trial name
- NCT06896110
- Testing
- Nivolumab, Azacitidine (AZA), lumbar puncture
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Andrew P. Groves
Diffuse Astrocytoma, IDH-Wildtype, Recurrent Glioblastoma
Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma
This phase II trial studies the best dose and effect of tocilizumab in combination with atezolizumab and stereotactic radiation therapy in treating glioblastoma patients whose tumor has come back after initial treatment…
- Trial name
- NCT04729959
- Testing
- Atezolizumab, Biospecimen Collection, Conventional Surgery
- Where
- 110 sites in United States
- Volunteers
- 61 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors
Radiation Therapy in Treating Patients With Progressive or Recurrent Malignant Brain Tumors
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Giving radiation therapy in different ways may kill more tumor cells.
- Trial name
- NCT00003574
- Testing
- surgical procedure, brachytherapy, intraoperative radiation therapy
- Where
- 9 sites in United States
- Sponsor
- New Approaches to Brain Tumor Therapy Consortium
Glioblastoma
Oral Gallium Maltolate for Recurrent Glioblastoma
This is a Phase 0 investigational study to assess the central nervous system penetration and tumoral concentration of gallium in patients with recurrent glioblastoma administered with preoperative gallium maltolate.
- Trial name
- NCT07515924
- Testing
- Gallium Maltolate, Surgical Intervention
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Medical College of Wisconsin
Brain and Central Nervous System Tumors
Thalidomide and Irinotecan in Treating Patients With Glioblastoma Multiforme Who Have Undergone Radiation Therapy
RATIONALE: Thalidomide may stop the growth of glioblastoma multiforme by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00039468
- Testing
- irinotecan hydrochloride, thalidomide
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- Dartmouth-Hitchcock Medical Center